USA flag logo/image

An Official Website of the United States Government

Ultrasensitive Detection Probes for Staphylococcus aureus Enterotoxins

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AI102432
Solicitation Year:
2012
Solicitation Topic Code:
NIAID
Solicitation Number:
PA10-123
Small Business Information
IMMUVEN, INC.
60 Hazelwood Dr champaign, IL -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Ultrasensitive Detection Probes for Staphylococcus aureus Enterotoxins
Agency: HHS
Contract: 1R43AI102432-01
Award Amount: $297,023.00
 

Abstract:

DESCRIPTION (provided by applicant): Staphylococcus aureus is a significant human health threat, producing exotoxins called superantigens, which are responsible for a range of diseases. S. aureus superantigens are associated with food-borne illnesses, pulmonary disease, pneumonia, toxic shock syndrome, exacerbated atopic dermatitis, delayed wound healing, and infectious endocarditis. The objective of the proposed work is to use high-affinity probes against these toxins, engineered by ImmuVen, to develop ultrasensitive detection assays. The probes include soluble T cell receptor proteins (IMV01, IMV02, IMV03, and IMV04) engineered for very high-affinity binding to Staphylococcal enterotoxins SEB, SEC, TSST-1, and SEA, respectively. It is thought that there are about 185,000 cases of Staphylococcal food-borne illness in the United States, annually, resulting in around 1750 hospitalizations with a cost of 1.5 billion. The hypotheses of this Phase I application are that ImmuVen can develop a high affinity Vbetaprotein that will bind SEA, the most important superantigen involved in Staphylococcal food-borne illness, and that this protein and the other already characterized soluble proteins can be used to develop a rapid multiplex assay for the detection of theseStaphylococcal superantigens. The work will be performed in collaboration with Prof. David Kranz (University of Illinois), and Drs. Sandra Tallent and Jeffrey DeGrasse at the FDA. The Specific Aims are: 1) To engineer a high affinity, soluble V against SEA; 2) To develop V -based assays to detect SEA, SEB, SEC, and TSST-1. In Phase II work, ImmuVen will further develop these assays, toward both a standardized food detection platform, and a clinical diagnostic tool. PUBLIC HEALTH RELEVANCE: Staphylococcus aureus is a significant human health threat, producing exotoxins called superantigens, which are responsible for a range of diseases. Staphylococcus aureus superantigens are associated with food-borne illness, pulmonary disease, pneumonia, TSS, exacerbated atopic dermatitis, delayed wound healing, and infectious endocarditis. It is thought that there are about 185,000 cases of Staphylococcal food-borne illness in the United States, annually, resulting in around 1750 hospitalizations with a cost of1.5 billion. ImmuVen technology will be used to develop detection tools to identify Staphylococcal superantigens in a variety of samples.

Principal Investigator:

Adam Chervin
217-979-1993
chervin@immuven.com

Business Contact:

Cheryl Quinn
858-768-1720
cquinn@immuven.com
Small Business Information at Submission:

IMMUVEN, INC.
60 Hazelwood Dr champaign, IL -

EIN/Tax ID: 126140071
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No